제이투케이바이오
Financials
Valuation Metrics
제이투케이바이오's Market Cap is ₩546B. At end of 2025 it was ₩503B. Ranked #1677 of 2,436 in KR market (top 69%), #1004 of 1,649 on KOSDAQ (top 61%), #185 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 54.62B KRW | KR#1,677/2,436 Sec#185/234 |
| Revenue | 36.82B KRW | KR#1,944/2,436 Sec#135/234 |
| Net Income | 4.03B KRW | KR#1,197/2,436 Sec#82/234 |
| Total Assets | 41.05B KRW | KR#2,261/2,436 Sec#208/234 |
| Net Assets | 33.90B KRW | KR#2,120/2,436 Sec#185/234 |
| Employees | 56 | KR#1,982/2,436 Sec#176/234 |
| Value | ||
| P/E | 13.56x | KR#914/2,436 Sec#56/234 |
| P/B | 1.61x | KR#1,830/2,436 Sec#132/234 |
| PEG | 0.02x | KR#156/2,436 Sec#6/234 |
| P/S | 1.48x | KR#1,650/2,436 Sec#95/234 |
| EV/EBITDA | 10.25x | KR#618/2,436 Sec#29/234 |
| FCF Yield | 3.71% | KR#954/2,436 Sec#58/234 |
| Profitability | ||
| ROE | 11.88% | KR#385/2,436 Sec#25/234 |
| ROA | 9.81% | KR#202/2,436 Sec#16/234 |
| Op. Margin | 12.23% | KR#384/2,436 Sec#33/234 |
| Revenue Growth | 53.08% | KR#282/2,436 Sec#29/234 |
| Earnings Growth | 567.57% | KR#98/2,436 Sec#6/234 |
| Financial Health | ||
| Debt Ratio | 121.09% | KR#683/2,436 Sec#83/234 |
| Total Debt | 400.0M KRW | KR#2,002/2,436 Sec#192/234 |
| FCF | 2.03B KRW | KR#1,082/2,436 Sec#77/234 |
| Cash | 8.88B KRW | KR#1,738/2,436 Sec#142/234 |
| Current Ratio | 3.74x | KR#467/2,436 Sec#76/234 |
| Net Debt/EBITDA | -1.88x | KR#311/2,436 Sec#18/234 |
| Dividend | ||
| Div. Yield | 2.67% | KR#709/2,436 Sec#38/234 |
| Div. Growth | 25.00% | KR#378/2,436 Sec#19/234 |
| Performance | ||
| 1Y Return | -0.85% | KR#728/2,436 Sec#55/234 |
| 1M Return | 12.53% | KR#221/2,436 Sec#14/234 |
| From 52W High | -21.18% | KR#198/2,436 Sec#10/234 |
| 1Y MDD | -37.95% | KR#454/2,436 Sec#34/234 |
| Trading | ||
| Volume | 25,085 shares | KR#1,748/2,436 Sec#176/234 |
| Foreign Own. | 1.36% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 689 KRW | KR#783/2,436 Sec#57/234 |
| BPS | 5,798 KRW | KR#1,332/2,436 Sec#97/234 |
Company Info
J2K Bio, established in 2016 and listed on KOSDAQ in March 2024, produces and sells cosmetic raw materials. The company is a cosmetic new material developer that swiftly meets client demands through innovative natural product methods and new material development using fermented microorganisms, offering a competitive edge. It focuses on developing new active ingredients derived from natural, organic, and biomaterials, providing safer alternatives to synthetic compounds. J2K Bio is headquartered in Cheongju-si, Chungcheongbuk-do.